45 results on '"Chennamsetty, Naresh"'
Search Results
2. Impact of virus-antibody interactions on viral clearance in anion exchange chromatography
3. Cyclization of N-Terminal Glutamic Acid to pyro-Glutamic Acid Impacts Monoclonal Antibody Charge Heterogeneity Despite Its Appearance as a Neutral Transformation
4. Streamlining the polishing step development process via physicochemical characterization of monoclonal antibody aggregates
5. Probing the Tryptophan Environment in Therapeutic Proteins: Implications for Higher Order Structure on Tryptophan Oxidation
6. Ion Mobility-Mass Spectrometry and Collision-Induced Unfolding Rapidly Characterize the Structural Polydispersity and Stability of an Fc-Fusion Protein.
7. Enhanced Precision of Circular Dichroism Spectral Measurements Permits Detection of Subtle Higher Order Structural Changes in Therapeutic Proteins
8. Insights in understanding aggregate formation and dissociation in cation exchange chromatography for a structurally unstable Fc-fusion protein
9. Ion Mobility-Mass Spectrometry and Collision-Induced Unfolding of Designed Bispecific Antibody Therapeutics
10. Modeling the Oxidation of Methionine Residues by Peroxides in Proteins
11. Role of harvest depth filtration in controlling product-related impurities for a bispecific antibody
12. Ion mobility-mass spectrometry and collision induced unfolding of designed bispecific antibody therapeutics
13. Developability Index: A Rapid In Silico Tool for the Screening of Antibody Aggregation Propensity
14. Design of Therapeutic Proteins with Enhanced Stability
15. Evaluation of a Non-Arrhenius Model for Therapeutic Monoclonal Antibody Aggregation
16. Understanding, Predicting, and Mitigating the Impact of Post-Translational Physicochemical Modifications, Including Aggregation, on the Stability of Biopharmaceutical Drug Products
17. Assessing detergent‐mediated virus inactivation, protein stability and impurity clearance in biologics downstream processes
18. Aggregation-Prone Motifs in Human Immunoglobulin G
19. Assessing detergent-mediated virus inactivation, protein stability and impurity clearance in biologics downstream processes
20. Tryptophan-Tryptophan Energy Transfer and Classification of Tryptophan Residues in Proteins Using a Therapeutic Monoclonal Antibody as a Model
21. Role of harvest depth filtration in controlling product-related impurities for a bispecific antibody.
22. Size exclusion chromatography for the characterization and quality control of biologics
23. Characterizing and understanding the formation of cysteine conjugates and other by-products in a random, lysine-linked antibody drug conjugate
24. Conformational stability and aggregation of therapeutic monoclonal antibodies studied with ANS and thioflavin T binding
25. Predictive tools for stabilization of therapeutic proteins
26. Investigation of anomalous charge variant profile reveals discrete pH-dependent conformations and conformation-dependent charge states within the CDR3 loop of a therapeutic mAb
27. Quadrupole Dalton-Based Controlled Proteolysis Method for Characterization of Higher Order Protein Structure
28. Purity Determination by Capillary Electrophoresis Sodium Hexadecyl Sulfate (CE-SHS): A Novel Application For Therapeutic Protein Characterization
29. Mesoscale modeling of complex binary fluid mixtures: Towards an atomistic foundation of effective potentials.
30. Cosurfactant and cosolvent effects on surfactant self-assembly in supercritical carbon dioxide.
31. Prediction of aggregation prone regions of therapeutic proteins
32. Purity Determination by Capillary Electrophoresis Sodium Hexadecyl Sulfate (CE-SHS): A Novel Application For Therapeutic Protein Characterization
33. Dynamic fluctuations of protein-carbohydrate interactions promote aggregation
34. Design of therapeutic proteins with enhanced stability
35. A screening tool for therapeutic monoclonal antibodies: Identifying the most stable protein and its best formulation based on thioflavin T binding
36. Prediction of protein binding regions
37. Glycosylation influences on the aggregation propensity of therapeutic monoclonal antibodies
38. Tryptophan-Tryptophan Energy Transfer and Classification of Tryptophan Residues in Proteins Using a Therapeutic Monoclonal Antibody as a Model
39. Design and Application of Antibody Cysteine Variants
40. Dynamic Fluctuations of Protein-Carbohydrate Interactions Promote Protein Aggregation
41. A screening tool for therapeutic monoclonal antibodies: Identifying the most stable protein and its best formulation based on thioflavin T binding.
42. Prediction of protein binding regions.
43. Glycosylation influences on the aggregation propensity of therapeutic monoclonal antibodies.
44. Molecular Simulation of Surfactant Self-assembly: From Mesoscale to Multi-scale Modeling.
45. Dynamic fluctuations of protein-carbohydrate interactions promote protein aggregation
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.